Corticorelin acetate injections for the treatment of peritumoral brain edema

Expert Opinion on Investigational Drugs

Volumn 18, Issue 9, 2009, Pages 1413-1419

  Moliterno, Jennifer A ^a   Henry, Euphael ^b   Pannullo, Susan C ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Brain tumors; Corticorelin acetate injections; Human corticotropin releasing factor; Peritumoral brain edema

Indexed keywords

CORTICORELIN ACETATE; CORTICOSTEROID; CORTICOTROPIN RELEASING FACTOR DERIVATIVE; DEXAMETHASONE; PLACEBO; UNCLASSIFIED DRUG;

BRAIN EDEMA; BRAIN TUMOR; CLINICAL TRIAL; CONTINUOUS INFUSION; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; HYPOTENSION; NONHUMAN; REVIEW; SIDE EFFECT; TASTE DISORDER; XEROSTOMIA;

ANIMALS; BRAIN EDEMA; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; CORTICOTROPIN-RELEASING HORMONE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; TREATMENT OUTCOME;

EID: 68849124489     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903190689     Document Type: Review

References (52)

1. Winn H, editor, Youmans neurological surgery. Philadelphia: Saunders Elsevier, 2004
2. Kaal EC, Vecht CJ. The management of brain edema in brain tumors. Curr Opin Oncol 2004;16(6):593-600
3. Wick W, Kuker W. Brain edema in neurooncology: radiological assessment and management. Onkologie 2004;27(3):261-6
4. Drappatz J, Wen PY. Management of vasogenic edema in patients with primary and metastatic brain tumors, 2008. Available from: http://www.uptodate. com/ patients/content/topic. do?topicKey=∼pu1pp.sZ/j6sMTk [Cited 4 Jun 2008]
5. Galicich JH, French LA, Melby JC. Use of dexamethasone in treatment of cerebral edema associated with brain tumors. Lancet 1961;81:46-53
6. Tjuvajev J, Uehara H, Desai R, et al. Corticotropin-releasing factor decreases vasogenic brain edema. Cancer Res 1996;56(6):1352-60
7. Villalona-Calero MA, Eckardt J, Burris H, et al. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. Ann Oncol 1998;9(1):71-7
8. Alberti E, Hartmann A, Schutz HJ, Schreckenberger F. The effect of large doses of dexamethasone on the cerebrospinal fluid pressure in patients with supratentorial tumors. J Neurol 1978;217(3):173-81
9. Das A, Banik NL, Patel SJ, Ray SK. Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities. Mol Cancer 2004;3(1):36
10. Gorman AM, Hirt UA, Orrenius S, Ceccatelli S. Dexamethasone pre-treatment interferes with apoptotic death in glioma cells. Neuroscience 2000;96(2):417-25
11. Green SB, Byar DP, Walker MD, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983;67(2):121-32
12. Naumann U, Durka S, Weller M. Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation? Oncogene 1998;17(12):1567-75
13. Weller M, Malipiero U, Aguzzi A, et al. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 1995;95(6):2633-43
14. Weller M, Schmidt C, Roth W, Dichgans J. Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology 1997;48(6):1704-9
15. Wolff JE, Denecke J, Jurgens H. Dexamethasone induces partial resistance to cisplatinum in C6 glioma cells. Anticancer Res 1996;16(2):805-9
16. Wolff JE, Jurgens H. Dexamethasone induced partial resistance to methotrexate in C6-glioma cells. Anticancer Res 1994;14(4A):1585-8
17. Marshall LF, King J, Langfitt TW. The complications of high-dose corticosteroid therapy in neurosurgical patients: a prospective study. Ann Neurol 1977;1(2):201-3
18. Pezner RD, Lipsett JA. Peptic ulcer disease and other complications in patients receiving dexamethasone palliation for brain metastasis. West J Med 1982;137(5):375-8
19. Warshaw AL, Welch JP, Ottinger LW. Acute perforation of the colon associated with chronic corticosteroid therapy. Am J Surg 1976;131(4):442-6
20. Weissman DE, Dufer D, Vogel V, Abeloff MD. Corticosteroid toxicity in neuro-oncology patients. J Neurooncol 1987;5(2):125-8
21. Schiff D. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. J Neurooncol 1996;27(3):235-40
22. Patthy M, Horvath J, Mason-Garcia M, et al. Isolation and amino acid sequence of corticotropin-releasing factor from pig hypothalami. Proc Natl Acad Sci USA 1985;82(24):8762-6
23. Vale W, Rivier C, Brown MR, et al. Chemical and biological characterization of corticotropin releasing factor. Recent Prog Horm Res 1983;39:245-70
24. Taylor AL, Fishman LM. Corticotropin-releasing hormone. N Engl J Med 1988;319(4):213-22
25. Angst MS, Dyck JB, Azarnoff DL, et al. Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. Clin Pharmacol Ther 1998;64(5):499-510
26. Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Brain Res Rev 1990;15(2):71-100
27. Joseph SA, Pilcher WH, Knigge KM. Anatomy of the corticotropin-releasing factor and opiomelanocortin systems of the brain. Fed Proc 1985;44(1 Pt 1):100-7
28. Koob GF, Heinrichs SC, Pich EM, et al. The role of corticotropin- releasing factor in behavioural responses to stress. Ciba Found Symp 1993;172:277-89; discussion 90-5
29. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981;213(4514):1394-7
30. Wei ET, Gao GC, Thomas HA. Peripheral anti-inflammatory actions of corticotropin-releasing factor. Ciba Found Symp 1993;172:258-68; discussion 68-76
31. Weiss SR, Post RM, Gold PW, et al. CRF-induced seizures and behavior: interaction with amygdala kindling. Brain Res 1986;372(2):345-51
32. Wei ET, Gao GC. Corticotropin-releasing factor: an inhibitor of vascular leakage in rat skeletal muscle and brain cortex after injury. Regul Pept 1991;33(2):93-104
33. Wei ET, Thomas HA. Anti-inflammatory peptide agonists. Annu Rev Pharmacol Toxicol 1993;33:91-108
34. Kiang JG, Poree L, Wei ET. Anti-inflammatory activity of corticotropin releasing factor: II. Mechanisms of action. Proc West Pharmacol Soc 1987;30:63-5
35. Chang CP, Pearse RV 2nd, O'Connell S, Rosenfeld MG. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 1993;11(6):1187-95
36. Kishimoto T, Pearse RV 2nd, Lin CR, Rosenfeld MG. A sauvagine/ corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci USA 1995;92(4):1108-12
37. Lovenberg TW, Liaw CW, Grigoriadis DE, et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 1995;92(3):836-40
38. Potter E, Sutton S, Donaldson C, et al. Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci USA 1994;91(19):8777-81
39. Tjuvajev J, Kolesnikov Y, Joshi R, et al. Anti-neoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway. In Vivo 1998;12(1):1-10
40. Graziani G, Tentori L, Muzi A, et al. Evidence that corticotropin- releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol 2007;264(1-2):44-9
41. Graziani G, Tentori L, Portarena I, et al. CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 2002;143(3):807-13
42. Dermitzaki E, Tsatsanis C, Gravanis A, Margioris AN. Corticotropin- releasing hormone induces Fas ligand production and apoptosis in PC12 cells via activation of p38 mitogen-activated protein kinase. J Biol Chem 2002;277(14):12280-7
43. Bale TL, Giordano FJ, Hickey RP, et al. Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci USA 2002;99(11):7734-9
44. Saphier PW, Faria M, Grossman A, et al. A comparison of the clearance of ovine and human corticotrophin-releasing hormone (CRH) in man and sheep: a possible role for CRH-binding protein. J Endocrinol 1992;133(3):487-95
45. Schopohl J, Hauer A, Kaliebe T, et al. Repetitive and continuous administration of human corticotropin releasing factor to human subjects. Acta Endocrinol (Copenh) 1986;112(2):157-65
46. Schurmeyer TH, Avgerinos PC, Gold PW, et al. Human corticotropin- releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion. J Clin Endocrinol Metab 1984;59(6):1103-8
47. Tanaka K, Nagata M, Itoh S, et al. Diagnostic study of a synthetic human corticotropin-releasing hormone (hCRH) in healthy adult males: its plasma pharmacokinetics and the effects on the urinary excretion of steroid hormones. Endocr J 1993;40(5):591-6
48. Corticorelin: ACTH RF, corticoliberin, corticotrophin-releasing hormone, corticotropin-releasing factor, human corticotropin-releasing hormone, ovine corticotrophin-releasing factor, Xerecept. Drugs R D 2004;5(4):218-9
49. Nink M, Krause U, Lehnert H, Beyer J. Safety and side effects of human and ovine corticotropin-releasing hormone administration in man. Klin Wochenschr 1991;69(5):185-95
50. Orth DN, Jackson RV, DeCherney GS, et al. Effect of synthetic ovine corticotropin-releasing factor. Dose response of plasma adrenocorticotropin and cortisol. J Clin Invest 1983;71(3):587-95
51. Rutz HP, Hofer S, Peghini PE, et al. Avoiding glucocorticoid administration in a neurooncological case. Cancer Biol Ther 2005;4(11):1186-9
52. Chu K, Jeong SW, Jung KH, et al. Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. J Cereb Blood Flow Metab 2004;24(8):926-33